Wooten Jenna G, Blikslager Anthony T, Marks Steve L, Law J Mac, Graeber Elizabeth C, Lascelles B Duncan X
Gastrointestinal Biology Research Laboratory, College of Veterinary Medicine, North Carolina State University, Raleigh, NC 27606, USA.
Am J Vet Res. 2009 Oct;70(10):1243-9. doi: 10.2460/ajvr.70.10.1243.
To assess in vivo effects of short-term administration of NSAIDs with varied cyclooxygenase (COX)-2 selectivity on pyloric and duodenal mucosa.
8 healthy dogs.
Each dog received deracoxib (2 mg/kg, PO, q 24 h for 3 days), firocoxib (5 mg/kg, PO, q 24 h for 3 days), meloxicam (0.2 mg/kg, PO, q 24 h for 1 day followed by 0.1 mg/kg, PO, q 24 h for 2 days), or placebo orally for 3 days; there was a 4-week interval between successive treatments. Prior to and on day 3 of drug administration, pyloric and duodenal mucosae were assessed endoscopically and biopsy specimens obtained for histologic examination. Cyclooxygenase-1 and -2 protein expressions were assessed (western blotting) and prostanoid concentrations measured (ELISAs). Data were analyzed by use of an ANOVA.
Drug administration did not significantly affect endoscopic mucosal scores, histologic scores, or COX-1 or -2 protein expression. The COX-1 protein expression was significantly higher in the pylorus than in the duodenum. Total prostaglandin and thromboxane B(2) (TXB(2)) concentrations were significantly greater in pyloric than in duodenal mucosa. Drug administration had no effect on prostaglandin or TXB(2) concentrations.
Prostanoid concentrations in gastric and duodenal tissues, and gross and histologic appearances, were not significantly affected by drugs with varied COX-2 selectivity. These findings suggested that, for these experimental conditions, there were no differences among the preferential and selective COX-2 inhibitors with regard to adverse effects on the gastric and duodenal portions of the gastrointestinal tract of dogs.
评估短期给予具有不同环氧化酶(COX)-2选择性的非甾体抗炎药(NSAIDs)对幽门和十二指肠黏膜的体内作用。
8只健康犬。
每只犬口服给予德拉考昔(2毫克/千克,每日一次,连续3天)、非罗考昔(5毫克/千克,每日一次,连续3天)、美洛昔康(0.2毫克/千克,每日一次,连用1天,随后0.1毫克/千克,每日一次,连用2天)或安慰剂,持续3天;连续治疗之间间隔4周。在给药前及给药第3天,通过内镜检查评估幽门和十二指肠黏膜,并获取活检标本进行组织学检查。评估环氧化酶-1和-2蛋白表达(蛋白质印迹法)并测量类前列腺素浓度(酶联免疫吸附测定法)。数据采用方差分析进行分析。
给药对内镜下黏膜评分、组织学评分或COX-1或-2蛋白表达无显著影响。COX-1蛋白表达在幽门中显著高于十二指肠。幽门黏膜中总前列腺素和血栓素B2(TXB2)浓度显著高于十二指肠黏膜。给药对前列腺素或TXB2浓度无影响。
具有不同COX-2选择性的药物对胃和十二指肠组织中的类前列腺素浓度以及大体和组织学外观无显著影响。这些发现表明,在这些实验条件下,在对犬胃肠道的胃和十二指肠部分的不良反应方面,优先和选择性COX-2抑制剂之间没有差异。